- Home
- IH vs GANX Comparison
IH vs GANX Comparison
Compare IH & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IH | GANX |
|---|---|---|
| Founded | 1996 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.8M | 78.2M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | IH | GANX |
|---|---|---|
| Price | $1.68 | $1.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 8.4K | ★ 511.2K |
| Earning Date | 03-31-2026 | 05-13-2026 |
| Dividend Yield | ★ 5.88% | N/A |
| EPS Growth | N/A | ★ 31.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $55,180.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.30 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.55 | $1.41 |
| 52 Week High | $3.60 | $4.34 |
Technical Indicators
Market Signals| Indicator | IH | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 44.86 | 41.94 |
| Support Level | $1.55 | $1.73 |
| Resistance Level | $1.83 | $2.11 |
| Average True Range (ATR) | 0.08 | 0.11 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 21.43 | 22.09 |
Price Performance
Historical ComparisonAbout IH iHuman Inc.
iHuman Inc is a Chinese company that uses artificial intelligence to create technology-driven puzzle products for children, making parenting easier and children happier. The company offers a range of intellectual development products that are designed to make the child-rearing experience more manageable for parents while turning intellectual development into a fun journey for children. Its revenue is generated from subscription fees paid by users for premium content on their self-directed and interactive online applications, as well as offline products and other sources.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.